Belgium· BE-AMP-SAM501537-00
Kyprolis 30 mg
A carfilzomib product containing carfilzomib, registered in Belgium by Amgen Europe. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Carfilzomib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XG02 (carfilzomib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Carfilzomib · ATC L01XG02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of carfilzomib costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Carfilzomib · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$230.65
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Carfilzomib
- Manufacturer
- Amgen Europe
- Country
- Belgium (BE)
- ATC code
- L01XG02
- ATC class
- Carfilzomib
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7719230
- be_apb3496007
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
238 interactions on record for carfilzomib.
Graded by severity as the source publishes them — 92 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Carfilzomib · interactions on record
238 records
- 92 severe
- 146 moderate
Most severe, free to view
- StanozololA14AA02severe
- OxymetholoneA14AA05severe
- PrasteroneA14AA07severe
- OxandroloneA14AA08severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Carfilzomib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandKyprolisParanova Oy
- SpainKYPROLIS 30 MG POLVO PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- NorwayKyprolisAbacus Medicine A/S
- PolandKyprolisAmgen Europe B.V.
- CzechiaKYPROLISAmgen Europe B.V., Breda
- SwedenKyprolis 30 mg Pulver till infusionsvätska, lösningAmgen Europe B.V.
- United KingdomKyprolis 30mg powder for solution for infusion vialsAmgen Ltd
- IcelandKyprolisAmgen Europe B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Kyprolis
- Norway · Kyprolis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1786f53a-7677-4ab5-97c2-e7e2a9627a81 GET /v1/drugs/1786f53a-7677-4ab5-97c2-e7e2a9627a81?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Kyprolis 30 mg",
"name_fr": "Kyprolis 30 mg",
"name_nl": "Kyprolis 30 mg",
"amp_code": "SAM501537-00",
"strengths": [
"30.0000",
"1500.0000",
"109.0000"
],
"pack_count": 1,
"substances": [
"Carfilzomib",
"Betadex",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Carfilzomib",
"authorisation_numbers": [
"EU/1/15/1060/003"
]
}See everything about carfilzomib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.